Company profile: VYNE Therapeutics
1.1 - Company Overview
Company description
- Provider of late-stage biopharmaceutical therapies for dermatologic and immuno-inflammatory diseases via the InhiBET BET Inhibitor Platform. Offerings include VYN201, a locally administered pan-BD BET inhibitor for vitiligo and other diseases with a soft drug approach, and VYN202, an oral BD2-selective BET inhibitor for moderate-to-severe plaque psoriasis and rheumatoid arthritis.
Products and services
- VYN202: Oral BD2-selective BET inhibitor developed to treat moderate-to-severe plaque psoriasis and rheumatoid arthritis with high potency and selectivity
- VYN201: Locally administered pan-BD BET inhibitor engineered to treat vitiligo and other diseases using a 'soft drug' approach
- InhiBET™ BET Inhibitor Platform: Platform for developing therapies targeting bromodomain and extra-terminal domain proteins for immuno-inflammatory diseases.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to VYNE Therapeutics
Alladapt
HQ: United States
Website
- Description: Provider of prescription therapeutics targeting food allergy; a privately held biopharmaceutical company focused on developing such treatments.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Alladapt company profile →
Escient Pharmaceuticals
HQ: United States
Website
- Description: Provider of bio-technical research and development services focused on advancing first-in-class G Protein-Coupled Receptor targeted drugs and therapies for neuro-immuno-inflammatory and autoreactive diseases. Pipeline includes EP262, an oral, once-daily small molecule MRGPRX2 antagonist for the potential treatment of mast cell-mediated diseases (including chronic urticarias and atopic dermatitis), and EP547, an oral, once-daily MRGPRX4 antagonist for cholestatic and uremic pruritus.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Escient Pharmaceuticals company profile →
Protalex
HQ: United States
Website
- Description: Provider of a class of biopharmaceutical drugs designed to treat autoimmune and inflammatory; a development stage company.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Protalex company profile →
Step Pharma
HQ: France
Website
- Description: Provider of CTPS1 inhibition therapies, developing STP938, an orally bioavailable CTPS1 inhibitor in clinical development for treating blood cancers and potentially solid tumors. The approach targets the CTPS1 enzyme to inhibit a key step in nucleotide synthesis to treat various cancers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Step Pharma company profile →
ImmuPharma
HQ: United Kingdom
Website
- Description: Provider of drug discovery and development focused on pioneering, novel therapies in specialist therapeutic areas with few existing treatments. Pipeline includes P140 (Lupuzor) in Phase 3 for SLE, P140 in Phase 2/3 for CIDP, BioAMB (amphotericin-B variant) in preclinical for serious fungal infections, and BioCIN (vancomycin-based) in preclinical for severe bacterial infections.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ImmuPharma company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for VYNE Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to VYNE Therapeutics
2.2 - Growth funds investing in similar companies to VYNE Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for VYNE Therapeutics
4.2 - Public trading comparable groups for VYNE Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →